Supplementary Material for: Antimicrobial Susceptibility among European Gram-Negative and Gram-Positive Isolates Collected as Part of the Tigecycline Evaluation and Surveillance Trial (2004-2014)

Abstract

<i>Background:</i> European centers (n = 226) involved in the Tigecycline Evaluation and Surveillance Trial (TEST, 2004-2014) submitted data and bacterial isolates. <i>Methods:</i>Minimal inhibitory concentrations and susceptibility were determined using Clinical and Laboratory Standards Institute methods and European Committee on Antimicrobial Susceptibility Testing breakpoints. <i>Results:</i> The rates of the following resistant pathogens increased from 2004 to 2014: extended-spectrum β-lactamase (ESBL)-positive <i>Escherichia coli</i> (from 8.9 to 16.9%), multidrug-resistant <i>Acinetobacter baumannii</i> complex (from 15.4 to 48.5%), and ESBL-positive <i>Klebsiella pneumoniae</i>(from 17.2 to 23.7%). The rate of methicillin-resistant <i>Staphylococcus aureus</i> was 27.5% in 2004 and 28.9% in 2014. Resistance to the carbapenems (imipenem and meropenem) was 37.4 and 14.5% for <i>A. baumannii</i> complex and <i>Pseudomonas aeruginosa</i>, respectively. Carbapenem resistance was ≤4.3% among the Enterobacteriaceae and 0.2% against <i>Streptococcus pneumoniae.</i> The resistance to tigecycline ranged between 7.4% against ESBL-producing <i>K. pneumoniae </i>and 0.0% against <i>S. aureus.</i><i>Conclusions:</i> The carbapenems and tigecycline were active against Enterobacteriaceae. Agents with activity against <i>A. baumannii</i> complex and <i>P. aeruginosa</i> are limited. The carbapenems, tigecycline, linezolid, and vancomycin were active against Gram-positive organisms